Skip to main content
Premium Trial:

Request an Annual Quote

Mobidiag Inks UK Distribution Deal With YouMed

NEW YORK (GenomeWeb) – Finnish molecular diagnostics firm Mobidiag has signed a distribution and commercialization deal with YouMed for its PCR-based Amplidiag platform.

Under the terms of the agreement, YouMed will sell and market Amplidiag and its associated menu of in vitro diagnostic tests for gastrointestinal infections, including bacterial, viral, and parasitic infections. The distribution agreement also includes the upcoming, automated Amplidiag Easy system.

Financial and other terms of the agreement were not disclosed.

"There is an unmet need in the UK molecular diagnostic market for accurate, reliable testing for gastrointestinal pathogens. We are confident the Mobidiag assays and systems can have a positive impact on management of patients suffering from these infections," YouMed Managing Director Christopher Brain said in a statement.

Mobidiag CEO Tuomas Tenkanen added that expanding its distribution network to include the UK was an important step for the company. Since the beginning of September, the company has also announced new distribution deals for Sweden and Norway, Central and Eastern Europe, and Portugal

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.